Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00230490
(Adverse findings from nonclinical carcinogenicity studies.)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who completed 48 weeks of treatment in study RNA200103-201
Patients who were determined to be treatment failures in study RNA200103-201
Patients who experienced a serious adverse event judged to be related to study drug in study RNA200103-201
Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive determinations in study RNA200103-201